International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Medication Use, Safety, and Health Services Research – A Comprehensive Review

[1]Pramod Bareth, [2]Dr. Peeyush Jain, [3]Md.Zulphakar Ali, [4]Mr. Pankaj Chasta

[1] Student of B. Pharmacy at Mewar University

[2] Dean of Department of Pharmacy, Mewar University

[3, 4] Assistant Professor at Mewar University

1. ABSTRACT :

The increasing intricacy of drug systems and treatment regimens has highlighted the importance of providing assurance that drugs are used safely and effectively. Adverse drug events (ADEs), polypharmacy, and medication errors are a major cause of patient morbidity and mortality, especially among vulnerable groups like the elderly. Health services research (HSR) offers a structured approach to assessing the delivery of healthcare, allowing the formulation of policies and practices to improve medication safety and maximize therapeutic benefit.

This review identifies current trends in medication use, discusses mechanisms of medication-related harm, and assesses risk mitigation strategies. Some of the areas covered are surveillance of adverse drug events, digital innovation, patient-centered care models, and the integration of clinical decision support tools. In addition, the article stresses the importance of pharmacovigilance, health policy, and real-world evidence in informing safer and more equitable medication use practices worldwide. The intersection of HSR with advances in technology and clinical science is a promising direction toward safer, more individualized, and more effective medication procedures.

2. Introduction

In contemporary medicine, drugs are unavoidable means for preventing and treating diseases. Yet, their misuse will cause enormous harm. The World Health Organization estimates that unsafe drug practices and drug mistakes are among the most common causes of preventable harm within healthcare systems globally {1}. These complications not only compromise patient safety but also create excessive financial burdens for health providers and society. The aim of health services research (HSR) is to study how individuals obtain healthcare services, the cost of care, and what the outcome is for the patient after the care has been received. Translated into drug use, HSR allows us to spot missing links in medication management, evaluates interventions, and guides policy updates. As delivery of health care transitions into value-based health care, embedding safety and efficiency in service for drug use is all the more necessary {2,3}.

3. Global Trends in Medication Use

The international pharmaceutical market is growing fast, with aging populations and higher rates of chronic diseases being major drivers. The number of prescriptions per patient has increased on average, particularly in industrialized countries where preventive and long-term medications are frequently prescribed {4}. This trend is even more significant in geriatric populations, where multimorbidity frequently requires polypharmacy.

Polypharmacy, the administration of five or more medications at the same time, is linked with increased risks of drug-drug interactions, non-adherence to medications, and elevated hospitalization rates {5,6}. Inappropriate prescribing—either by omitting required medications or adding unnecessary or potentially injurious medications—also continues to be a worldwide issue. Initiatives like medication review services and the utilization of prescribing tools (e.g., STOPP/START criteria) are designed to maximize pharmacotherapy, especially in the elderly {7,8}.

Developing countries have another challenge: unequal access to vital drugs. Variable drug availability, prices, and absence of uniform prescribing practices can lead to diminished treatment results and greater health inequalities {9}.

4. Adverse Drug Events and Medication Errors

Adverse drug events (ADEs) are harm caused by medication use, such as side effects, overdoses, allergic reactions, and interactions. They are a frequent reason for emergency department visits and hospitalizations, particularly in the elderly and in individuals with multiple chronic conditions {10,11}. Medication mistakes—avoidable occurrences that have the potential to lead to improper medication use or injury—can happen at prescribing, dispensing, administration, or monitoring. Research indicates that errors are highest at the prescribing level, with errors in administration due to communication breakdown or insufficient patient education {12}.

There are various methods health systems have used to mitigate ADEs and medication mistakes:

•\tComputerized Physician Order Entry (CPOE): Prevents transcription mistakes and allows automatic dosage verification {13}.

•\tClinical Decision Support Systems (CDSS): Offer real-time drug interaction alerts, allergy alerts, and dosing recommendations {14}.

•\tBar-coded Medication Administration (BCMA): Facilitates right patient–right drug verification {15}.

Even with these systems, effective implementation is largely dependent on workflow integration and continuous training.

5. Pharmacovigilance and Real-World Surveillance

Pharmacovigilance is the art and science of monitoring, evaluating, and preventing adverse drug reactions or other drug-related issues. Spontaneous reporting systems like the U.S. FDA's MedWatch and WHO's VigiBase are key tools for identifying safety signals that were not detected during clinical trials {16}.

With the expansion of real-world data (RWD) from electronic health records, insurance claims, and patient registries, pharmacovigilance is becoming more proactive and all-encompassing surveillance. These big data enable post-marketing safety studies, cohort analyses, and signal amplification through machine learning {17,18}.

Challenges are underreporting, variable quality of data, and challenges in correlating exposure to drugs with outcomes. One of the methods being explored to enhance accuracy and depth of surveillance is combining patient-reported outcomes (PROs) and wearable technology information {19}.

6. Patient-Centered Medication Management

Patient-centered care aims at individualized treatment plans that honor patients' values, needs, and preferences. In medication management, this method is especially useful in enhancing adherence, enhancing outcomes, and lowering healthcare expenditures.

Shared decision-making (SDM) entails clinicians and patients working together in making decisions regarding treatment, balancing between clinical evidence and patient priorities {20}. Pharmacists are central by performing medication therapy management (MTM), patient education, and warning signs such as possible interactions or non-adherence {21}.

Innovative technologies like medication reminder applications, telepharmacy, and home-delivery services improve convenience and ensure continuity of care, particularly for patients with mobility or access limitations to healthcare facilities {22,23}.

7. Medication Reconciliation and Transitions of Care

In transitions of care—hospital admission, discharge, or transfer—patients are at risk for medication discrepancies. Research indicates that 70% of patients have an unintended change in medication during transitions, resulting in adverse events or readmission {24}.

Medication reconciliation is the practice of developing the most current and accurate list of all medications a patient is currently taking and utilizing this list to verify proper medication administration. It is best done by trained professionals, usually pharmacists or nurses, working within multidisciplinary teams {25}.

The application of interoperable electronic health records (EHRs) in care settings further supports medication continuity. E-prescribing and secure communication systems assist in reducing discrepancies and enhancing outcomes {26}.

8. Health Policy, Equity, and Access

Health services research is an important input to drug-related health policy. Formulary management decisions, pricing policies, and coverage policies need to be evidence-informed and equity-oriented.

Health Technology Assessment (HTA) assesses the clinical effectiveness, safety, and cost-effectiveness of drugs and is applied everywhere to inform reimbursement and coverage decisions {27}. HTA frameworks, however, have to account for the local environment, especially in low- and middle-income countries where cost and population health needs are dramatically different.

Policies that enhance generic drug use, promote efficiency in drug approval, and control pharmaceutical promotion also make medication use safer and more available {28}.

Health disparities—geographic, racial, and economic access barriers to medication—must be tackled through targeted interventions like community pharmacy outreach, school-based, and subsidized care initiatives {29}.

9. Digital Innovations in Medication Safety

The digitalization of healthcare has transformed medication safety with various technologies:

• Electronic Prescribing (eRx): Reduces errors in handwriting and ensures correct prescription filling.

• Smart Pill Dispensers and Reminders: Monitor compliance and remind caregivers if doses are not taken.

• Artificial Intelligence (AI) Algorithms: Anticipate ADEs by computing patient-specific risk factors {30}.

• Natural Language Processing (NLP): Derive medication-related information from unstructured clinical text to recognize safety trends.

These innovations, however, require careful implementation. Digital divide, user resistance, and privacy concerns must be addressed to ensure equitable benefits from health technology.

10. Conclusion

Medication use and safety are foundations of high-quality healthcare delivery. As polypharmacy increases, the population ages, and care environments become increasingly complex, so too do the challenges facing medication-related risks. Health services research offers the tools and concepts for understanding, quantifying, and optimizing the use of medications across a wide range of clinical environments.

The synergy between technology, patient-centered care, and evidence-based policies presents a promising direction for minimizing medication-related harm and improving health outcomes. In the future, interprofessional collaboration, international knowledge exchange, and ongoing quality improvement will be crucial to make medication safety a standard of care rather than a goal.

As health systems continue to develop, the incorporation of real-world evidence, artificial intelligence, and community-based programs will be essential in ensuring equitable, safe, and effective use of medication for everyone.

REFERENCES:

{1} World Health Organization. (2017). Medication Without Harm – WHO Global Patient Safety Challenge.

https://www.who.int/initiatives/medication-without-harm

{2} Bates, D. W., et al. (2018). "Global priorities for patient safety research." BMJ Quality & Safety, 27(7), 577-582.

{3} Ayanian, J. Z., et al. (2019). "The Role of Health Services Research in Improving Health Care." NEJM, 381(8), 728-737.

{4} OECD. (2021). Health at a Glance 2021: OECD Indicators.

{5} Maher, R. L., et al. (2014). "Clinical consequences of polypharmacy in elderly." Expert Opinion on Drug Safety, 13(1), 57-65.

{6} Garfinkel, D., et al. (2015). "Inappropriate medication use in elderly people." Archives of Internal Medicine, 165(9), 1066–1072.

{7} Hughes, C. M., et al. (2002). "The misuse of over-the-counter products by older people." Age and Ageing, 31(6), 489–491.

{8} Alexander, G. C., et al. (2017). "Trends in Prescription Drug Use Among Adults in the United States." JAMA, 314(17), 1818–1831.

{9} WHO. (2022). Medication Safety in Transitions of Care.

{10} Leape, L. L., et al. (1995). "Preventing Medical Injury." New England Journal of Medicine, 329(27), 1965-1972.

{11} Bates, D. W. (1995). "Medication errors and adverse drug events in hospitalized patients." JAMA, 274(1), 29-34.

{12} Kaushal, R., et al. (2003). "CPOE and medication errors." JAMA, 289(10), 1239-1245.

{13} Poon, E. G., et al. (2010). "Effect of Bar-Code Technology on the Safety of Medication Administration." NEJM, 362(18), 1698-1707.

{14} FDA. (2023). MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

{15} WHO Collaborating Centre for International Drug Monitoring. VigiBase. https://www.who-umc.org/vigibase/vigibase/vigibase

{16} Bate, A., et al. (2009). "Data mining techniques in pharmacovigilance." Drug Safety, 32(10), 865-875.

{17} Harpaz, R., et al. (2012). "Text mining for adverse drug events." Journal of Biomedical Informatics, 45(5), 885-892.

{18} Elwyn, G., et al. (2012). "Shared decision making: a model for clinical practice." Journal of General Internal Medicine, 27(10), 1361–1367.

{19} Jansen, J., et al. (2007). "Patient decision aids and adherence to treatment." BMJ, 334(7603), 760.

{20} Gillespie, U., et al. (2009). "Impact of medication reviews on hospital readmissions." Archives of Internal Medicine, 169(9), 894-900.

{21} Kardas, P., et al. (2013). "Determinants of patient adherence." Therapeutics and Clinical Risk Management, 9, 91–102.

{22} Institute for Healthcare Improvement. (2011). Medication Reconciliation Review.

{23} Boockvar, K. S., et al. (2004). "Effect of medication reconciliation on adverse drug events." Archives of Internal Medicine, 164(18), 2044–2050.

{24} Mueller, S. K., et al. (2012). "Hospital-based medication reconciliation practices." Archives of Internal Medicine, 172(14), 1057–1069.

{25} Schnipper, J. L., et al. (2009). "Effect of EHR-based tools on medication safety." Archives of Internal Medicine, 169(8), 771–780.

{26} Sorensen, T. D., et al. (2019). "The Impact of Health Policy on Medication Safety." Research in Social and Administrative Pharmacy, 15(6), 730–737.

{27} Chalkidou, K., et al. (2009). "Comparative effectiveness research and HTA." Health Affairs, 28(5), 1340–1350.

{28} Institute of Medicine. (2001). "Crossing the Quality Chasm: A New Health System for the 21st Century."

{29} Patel, M. X., et al. (2021). "Digital health technology and medication adherence." Frontiers in Pharmacology, 12, 748698.

{30} Sendak, M., et al. (2020). "Real-world applications of machine learning in health care." Science Translational Medicine, 12(561), eaay8070.